Who are SCOPOLAMINE's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Enlon-Plus, oxybutynin immediate release, Neostigmine with glycopyrrolate, ACs, Fentanyl/Atropine/Succinylcholine, Neostigmine + Glycopyrrolate.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/scopolamine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

SCOPOLAMINE — Competitive Intelligence Brief

SCOPOLAMINE (SCOPOLAMINE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticholinergic [EPC]. Area: Neuroscience.

marketed Anticholinergic [EPC] Muscarinic acetylcholine receptors Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

SCOPOLAMINE (SCOPOLAMINE).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
SCOPOLAMINE TARGET	SCOPOLAMINE		marketed	Anticholinergic [EPC]	Muscarinic acetylcholine receptors	1979-01-01
Enlon-Plus	Atropine Sulfate	Alcon Labs Inc	marketed	Antimuscarinic agent	Muscarinic acetylcholine receptors	1960-01-01
oxybutynin immediate release	oxybutynin immediate release	Astellas Pharma Inc	marketed	Anticholinergic	Muscarinic acetylcholine receptors (M2 and M3)
Neostigmine with glycopyrrolate	Neostigmine with glycopyrrolate	The Cleveland Clinic	marketed	Acetylcholinesterase inhibitor with anticholinergic agent	Acetylcholinesterase; muscarinic acetylcholine receptors
ACs	ACs	GlaxoSmithKline	marketed	Anticholinergic agent	Muscarinic acetylcholine receptors (non-selective or subtype-specific)
Fentanyl/Atropine/Succinylcholine	Fentanyl/Atropine/Succinylcholine	King Saud University	marketed	Anesthetic combination (opioid + anticholinergic + neuromuscular blocker)	Mu-opioid receptor (fentanyl); muscarinic acetylcholine receptors (atropine); nicotinic acetylcholine receptors at neuromuscular junction (succinylcholine)
Neostigmine + Glycopyrrolate	Neostigmine + Glycopyrrolate	Merck Sharp & Dohme LLC	marketed	Acetylcholinesterase inhibitor with anticholinergic agent	Acetylcholinesterase (neostigmine); Muscarinic acetylcholine receptors (glycopyrrolate)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticholinergic [EPC] class)

· 2 drugs in this class
Mylan Ireland Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SCOPOLAMINE — Competitive Intelligence Brief. https://druglandscape.com/ci/scopolamine. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab